Dr. Alexander Shtilbans is a board certified neurologist whose clinical interest lies in the area of neurodegenerative diseases, particularly Parkinsons disease. He began his career as a molecular biologist in Neuroscience and, after obtaining his Ph.D., transitioned into clinical Neurology in order to work with patients and gain a better understanding of the clinical course of these diseases.
Dr. Shtilbans received his medical degree from Mount Sinai School of Medicine, where he also completed his residency in Neurology and served as a chief resident. Subsequently, he trained with Dr. Stanley Fahn during his clinical fellowship in Movement Disorders at Columbia University. Dr. Shtilbans has a longstanding interest in translational research and is currently involved in several clinical trials in Amyotrophic Lateral Sclerosis.
As a physician scientist, Dr. Shtilbans is interested in developing new therapies that will slow down the progression of neurodegenerative diseases. His goal is to better understand molecular mechanisms of the neurodegenerative processes by being actively involved in both clinical and basic science research.
He has been publishing his research findings for over a decade and has received awards from the American Academy of Neurology.
Assistant Attending, Hospital for Special Surgery
Assistant Professor, Weill Medical College of Cornell University
Movement Disorders: Parkinson's disease, Tremor, dystonia, myoclonus, restless leg syndrome, tardive dyskinesia
Botox injections for cervical dysdonia, blepharospasms, hemifacial spasms, spasticity.
Deep brain stimulation (DBS) programming and adjustments.
Medical Student Prize for Excellence in Neurology, American Academy of Neurology (2006)
Extended Neuroscience Award, American Academy of Neurology (2006)
Medical Student Essay: Novel pathogenic mutations in human mitochondrial DNA genes
American Academy of Neurology
Movement Disorders Society
Blue Cross Blue Shield PPO HMO POS
Blue Cross Blue Shield Pathway
Blue Cross Blue Shield Pathway Enhanced
EmblemHealth Select Care
Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may have coverage subject to the availability of 'out-of-network' benefits.
Dr. Alexander Shtilbans accepts the following insurance plans. Please check to see if your insurance is on this list before proceeding.
Please note, if your insurance is not on this list, you may still have coverage subject to the availability of out-of-network benefits.
If you do not wish to go out-of-network, our HSS Connect service will help you find an appropriate doctor.
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Shtilbans as of January 24, 2019.
•Adamas – Speakers' Bureau
•Neurocrine – Speakers' Bureau
Teva – Speakers' Bureau
•UCB – Speakers' Bureau
•US Worldmeds – Speakers' Bureau
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
Doctor of Medicine, Mount Sinai School of Medicine, New York, NY, 2006
Ph.D., Biological Sciences, St. Petersburg Technological Institute, St. Petersburg, Russia, 2002
Masters, Biology, New York University, Graduate School of Arts and Science, New York, NY, 1997
Internal Medicine, St. Luke's Roosevelt Hospital Center, New York, NY, 2007
Neurology, Mount Sinai Medical Center, New York, NY, 2010
Movement Disorders, Columbia University Medical Center, New York, NY 2011
American Board of Psychiatry and Neurology (Neurology), 2010
Shtilbans A, Choi S, Fowkes M, Khitrov G, Shahbazi M, Ting J, Zhang W, Sun Y, Sealfon S, Lange D. Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler, 2011; 12(4):250-6.
Shtilbans A, Shanske S, Goodman S, Sue C, Bruno C, Johnson T, Lava N, Waheed N, DiMauro S. G8363A mutation in the mtDNA tRNALys gene: another cause of Leigh syndrome.
J Child Neurol, 2000; 15(11):759-761.
Shtilbans A, El-Schahawi M, Malkin E, Shanske S, Musumeci O, DiMauro S.
A novel mutation in the mitochondrial DNA transfer ribonucleic acid Asp gene in a child with myoclonic epilepsy and psychomotor regression. J Child Neurol, 1999; 14:610-613.
Andreu AL, Bruno C, Dunne TC, Tanji K, Shanske S, Sue CM, Krishna S, Hadjigeorgiou GM, Shtilbans A, Bonilla E, DiMauro S. A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria. Ann Neurol, 1999; 45(1):127-130.
Andreu AL, Bruno C, Shanske S, Shtilbans A, Hirano M, Krishna S, Hayward L, Systrom DS, Brown RH Jr, DiMauro S. Missense mutation in the mtDNA cytochrome b gene in a patient with myopathy. Neurology, 1998; 51(5):1444-1447.
Kirov N, Shtilbans A, Rushlow C. Isolation and characterization of a new gene encoding a member of the HIRA family of proteins from Drosophila melanogaster. Gene, 1998; 212(2):323-332.
Hirano M, Shtilbans A, Mayeux R, Davidson MM, DiMauro S, Knowles JA, Schon EA.
Apparent mtDNA heteroplasmy in Alzheimer’s Disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. Proc Natl Acad Sci USA, 1997; 94:14894-14899.
Study of genetic biomarkers and novel treatments for Neurodegenerative diseases including Parkinson's disease and ALS.
New Patient Forms (pdf)